Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ATP 128

Next Previous
Drug Profile

ATP 128

Alternative Names: ATP128; KISIMA®cancer vaccine

Latest Information Update: 16 Oct 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amal Therapeutics
  • Developer Amal Therapeutics; Boehringer Ingelheim
  • Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines; Protein vaccines; Recombinant fusion proteins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Colorectal cancer

Most Recent Events

  • 08 Sep 2024 Efficacy data from the phase I/II trial in Colorectal cancer (Late-stage disease, Combination therapy, Metastatic disease, Second-line therapy or greater) presented at the CRI-ENCI: 8th Annual International Cancer, Immunotherapy Conference (CICON-2024)
  • 20 Sep 2023 Immunogenicity data from the phase Ib/II KISIMA-01 trial in colorectal cancer presented at the 7th Annual International Cancer, Immunotherapy Conference (CRI-ENCI-AACR-2023)
  • 28 Mar 2023 No recent reports of development identified for preclinical development in Colorectal-cancer in Switzerland (SC, Injection)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top